Drug intelligence / Profile preview

mRNA-1566

Development stage: Preclinical
Lead developer: Merck
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics

Overview

mRNA-1566 is an investigational mRNA-based vaccine candidate developed by Moderna Therapeutics (now Moderna) as part of a collaboration with Merck for antiviral applications. It encodes an undisclosed viral antigen to induce immune responses, leveraging lipid nanoparticle-encapsulated modified mRNA technology for transient protein expression and immunogenicity. Licensed to Merck in 2016 following promising preclinical results by Moderna's Valera team, it represents an early program in mRNA vaccine therapeutics against viral diseases, with no public disclosure of the specific viral target, mechanism details, or advancement to clinical trials.[3][4][9]

Other names: MRK-V213MRK-V-213MRK-V 213

Beyond the preview

Go deeper on mRNA-1566.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mRNA-1566.

Explore the full profile